Advaita Bioinformatics was founded in 2005 as a spin-off from Wayne State University. The company’s mission is to enable a true personalized medicine approach by providing advanced tools that can leverage omics and genomics data to improve drug development and patient care. The company’s expertise in big data, AI and machine learning has led to the development of IP related to: i) the identification of mechanisms of action from omics data, ii) the integration of multiple types of data and iii) the unsupervised discovery of patient subgroups and disease subtypes. These technologies, available either as SaaS or concierge services, can be used to improve the success of clinical trials by distinguishing between respondents and non-respondents, design optimal treatments by distinguishing between more and less aggressive types of diseases, repurpose drugs based and predict side-effects. Over 14,000 researchers from all over the world are currently using the Advaita’s SaaS platform.
Sorin Draghici is the founder and CEO of Advaita Bio, a spinout of his research lab at Wayne State University. He is also an associate dean for Innovation and Entrepreneurship, and director, James and Patricia Anderson Engineering Ventures Institute in the College of Engineering at Wayne State University. He currently holds the Robert J. Sokol, MD Endowed Chair in Systems Biology, as well as appointments as full professor in the Departments of Computer Science and Obstetrics and Gynecology. His work is focused on research in artificial intelligence, machine learning and data mining techniques applied to bioinformatics and computational biology, area in which he holds several patents. He has published over 150 peer-reviewed journal and conference publications as well as 8 book chapters and two books. To date, his work has gathered over 10,000 Google Scholar citations. Over 14,000 researchers from all over the world are currently using the Advaita’s platform.
Advaita Bioinformatics has had a busy year. Although they have not yet raised VC money, they did get another $720K in non-dilutive funding. Importantly, sales of existing products are up. The company recently sold a 15-seat site license to Stanford. Early reports indicate the customer loves it. The company is currently working on the clinical trial software.
Get Up & Go
Get Up & Go makes convenient energy products that taste incredible, equivalent to an energy shot or cup of coffee.
Pathware (Formerly Medkairos)
Pathware is automating the cancer biopsy assessment process. 1 out of every 5 biopsies taken fail to collect adequate tissue samples to come to a diagnosis. We are a medical technology company building the Bioptic™ system to increase the accuracy of cancer sample collection and reduce the time and labor required to reach a diagnosis. Pathware has developed the Bioptic platform to verify sample quality at the point of care to make sure that patients will only have to undergo a biopsy procedure once. Bioptic™ uses a proprietary cartridge, camera, and image processing software package to verify that a sample has enough tissue to make a diagnosis - work traditionally done by a pathologist and a microscope.
Michael Moore founded MedKairos to address challenges that he saw throughout his medical education at the University of Michigan. Prior to entering the time constraints of residency, he decided to take a leave from his medical training to develop this venture full time and, ultimately, have a global impact on patient care.
Pathware (formerly MedKairos), has continued to make great strides in its effort to streamline and standardize cancer diagnostic workflows. They do this with their flagship product, Bioptic™, a portable unit able to image and assess a biopsy sample in seconds with no staining or additional training required. All images are uploaded to their secure and proprietary cloud infrastructure to expand the platform’s capabilities with education, research, and machine learning. Since their pitch at NEF, their team has grown to five full time employees, proved the functionality of their platform, lined up 5 hospitals for pilots this summer, and expanded their advisory board to include the VP of Sales at Philips, the previous CIO of United Healthcare and Optum Health, and the two previous presidents of the Digital Pathology Association. Additionally, they were recognized as the number one health technology company at South By Southwest earlier this year. Together, they have been able to secure $800k in investment with an additional $1.5MM set to close in the near future to propel them through their clinical studies later this summer. In the next six months they plan to secure clearance from the FDA, freeze the design of their MVP, and initiate the soft launch of the product into their pilot institutions as they seek their Series A financing to support their scale into the marketspace.